HeartBeam this week announced it appointed Lance Myers to chief artificial intelligence scientist.
Myers will be responsible for driving HeartBeam’s digital health data analytics and body-worn biosensor technology company’s AI strategy and how it is applied to its core technology.
“We’ve made tremendous progress with our deep learning approach with data demonstrating that combining HeartBeam AI with a vector-based approach delivered equivalent performance to a 12-lead ECG and greatly improved detection of atrial flutter over a single-lead ECG,” CEO and Founder Branislav Vajdic said in a news release. “As we enter the next phase of development, we’re pleased to have an industry leader of Lance’s caliber join our team. His insights and expertise will have an immediate impact as we strive to transform cardiac care by harnessing the power of AI with our data-rich technology.”
Prior to joining and becoming chief AI scientist, Myers was an AI advisor for HeartBeam. He was also head of cardiovascular devices at Verily Life Sciences and held numerous roles and varying responsibilities at XAI.health, Sentrian, VivoSense, Boston Neurosciences, and Vivometrics.
“Being appointed as Chief AI Scientist is both an honor and an exciting challenge. The HeartBeam technology, when combined with advanced AI, has tremendous potential to unlock and deliver groundbreaking cardiac management solutions spanning diagnostics, screening, predictive analytics and closed-loop patient management – where detection, intervention and real-time measurement continually refine and optimize treatment outcomes. By leveraging longitudinal trends and increasing user data, we can uncover new insights, pushing the boundaries of AI in cardiac care and bringing transformative advancements to patients,” Myers said.
More about HeartBeam’s technology
HeartBeam’s core technology captures electrical signals from the heart in three dimensions to provide total heart intelligence. The company’s first use of the technology is a cable-free, credit card-sized device that can synthesize a 12-lead ECG.
By using AI to analyze data-rich signals, HeartBeam thinks the technology could improve diagnostic accuracy and enable a more personalized approach to cardiac care.
The HeartBeam device measures a series of ECG readings and uses AI to analyze the data. This provides a longitudinal view of the patient’s cardiac status and goes beyond the gold-standard 12-lead ECG.
HeartBeam AI is currently under development, and the HeartBeam system is being reviewed by the FDA.
